ReviewBJA education2023
Empirical decision-making for antimicrobial therapy in critically ill patients.
Review in BJA education, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Hour-1 Sepsis Bundle: Updated Evidence.Journal of clinical medicine · 2026Review
- Stratified cumulative antibiograms and antimicrobial resistance trends among hospitalized patients in a Chinese tertiary hospital: a 7-year retrospective study.World journal of microbiology & biotechnology · 2026Article
- Impact of appropriate antimicrobial therapy on patient outcomes and antimicrobial use: a sub analysis of the DIANA Study Dataset.Intensive care medicine · 2026Article
- Multidrug-resistant organism colonization in critically ill cirrhotic patients: Marker or mediator of mortality?World journal of hepatology · 2026Article
- Clinical and Microbiological Characteristics and Antimicrobial Susceptibility Patterns of Multidrug-ResistantInfection and drug resistance · 2026Article
- Management of acute pyelonephritis in pregnancy in emergency settings: A comparative study of conservative therapy and renal drainage.Journal of education and health promotion · 2026Article
- Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus Colistin + Meropenem (COL + MER) for the Treatment of Infections Caused by Metallo-β-Lactamase (MBL)-Producing Enterobacterales in Italy.PharmacoEconomics · 2025Article
- Role of artificial intelligence in ICU therapeutic decision-making for severe infections.Current opinion in critical care · 2025Review
- "Dusting Off the Cobwebs": Rethinking How We Use New Antibiotics.Antibiotics (Basel, Switzerland) · 2025Review
- Novel therapies and interventions in sepsis and septic shock.BJA education · 2025Review
- Evaluation of T2 Magnetic Resonance (T2MRAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.